Transcenta Holding Limited (HKG:6628)
0.7150
-0.0200 (-2.72%)
Nov 3, 2026, 4:08 PM HKT
Transcenta Holding Revenue
Transcenta Holding had revenue of 23.60M CNY in the half year ending June 30, 2026, with 417.02% growth. This brings the company's total for the last twelve months to 28.32M, up 201.03% year-over-year. In the year 2025, Transcenta Holding had annual revenue of 7.44M, down -33.98%. That makes Transcenta Holding the 40,564th largest company in the world by revenue and 2,481st in Hong Kong.
Revenue (ttm)
28.32M CNY
Revenue Growth
+201.03%
P/S Ratio
9.34
Revenue / Employee
188.81K CNY
Employees
150
Market Cap
305.27M HKD
Revenue by Geography
- Chinese Mainland 6.63M 89.1%
- United States of America 808.00K 10.9%
Fiscal year ended Dec 31, 2025 See the full Transcenta Holding breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.44M | -3.83M | -33.98% |
| Dec 31, 2024 | 11.26M | -42.59M | -79.09% |
| Dec 31, 2023 | 53.85M | -48.04M | -47.15% |
| Dec 31, 2022 | 101.89M | 51.65M | 102.80% |
| Dec 31, 2021 | 50.24M | -30.74M | -37.96% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Uni-Bio Science Group | 549.77M |
| 3D Medicines | 412.66M |
| Cutia Therapeutics | 383.95M |
| JW (Cayman) Therapeutics Co. | 333.25M |
| Kintor Pharmaceutical | 90.90M |
| Wuhan YZY Biopharma | 67.26M |
| Shanghai Bio-heart Biological Technology | 44.39M |
| Brii Biosciences | 40.23M |
Transcenta Holding News
- 15 days ago - Transcenta Appoints Former Sino Biopharmaceutical CFO Jennie Ma - Nasdaq
- 10 months ago - Transcenta Collaborates With EirGenix To License HiCB Platform - Nasdaq